Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 25, 2021
Product Information [Line Items]        
Risks and Uncertainties in Entity's Business We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022.      
Net cash provided by (used in) operating activities $ 20,287,000 $ (7,892,000)    
Cash Equivalents, at Carrying Value 29,400,000      
Restricted Cash   $ 250,000  
Fair value of investment securities $ 76,000    
Description of property plant and equipment useful lives ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years      
Cash and cash equivalents and restricted cash balance $ 25,800,000      
Federal depository insurance 900,000      
Uninsured 24,900,000      
Breakage revenue 400,000      
Contract with Customer, Liability 3,104,000   2,939,000  
Deferred Revenue 2,900,000      
R&D costs incurred 35,000 115,000    
Cooperative Incentive Promotion Costs [Member]        
Product Information [Line Items]        
Advertising and incentive promotion expenses $ 60,000 $ 168,000    
Minimum [Member]        
Product Information [Line Items]        
[custom:ContractWithCustomerEstimatedLife] 12 months      
Maximum [Member]        
Product Information [Line Items]        
[custom:ContractWithCustomerEstimatedLife] 36 months      
Investment Shares [Member]        
Product Information [Line Items]        
Investment owned, balance shares       1,260,619
Investment owned, at fair value     $ 76,000 $ 315,000
Diagnostic Services [Member]        
Product Information [Line Items]        
Percentage of revenue from diagnostic services 69.00% 57.00%